Tribute Pharmaceuticals Canada Inc. - FORM 10-Q - EX-32.1 - CERTIFICATION - November 10, 2014

Attached files

file filename
EX-31.1 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc.tbuff_ex311.htm
EX-10.3 - INTELLECTUAL PROPERTY SECURITY AGREEMENT, DATED OCTOBER 1, 2014 - Tribute Pharmaceuticals Canada Inc.tbuff_ex103.htm
EX-10.1 - FIRST AMENDMENT TO CREDIT AGREEMENT - Tribute Pharmaceuticals Canada Inc.tbuff_ex101.htm
EX-10.2 - WARRANT, DATED OCTOBER 1, 2014, ISSUED TO SWK FUNDING LLC IN CONNECTION WITH THE FIRST AMENDMENT TO THE CREDIT AGREEMENT AND GUARANTEE - Tribute Pharmaceuticals Canada Inc.tbuff_ex102.htm
EX-31.2 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc.tbuff_ex312.htm
EX-32.2 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc.tbuff_ex322.htm
EX-10.5 - FORM OF BROKER WARRANT, DATED JULY 15, 2014, ISSUED TO THE UNDERWRITERS IN THE FINANCING THAT CLOSED ON JULY 15, 2014. - Tribute Pharmaceuticals Canada Inc.tbuff_ex105.htm
EXCEL - IDEA: XBRL DOCUMENT - Tribute Pharmaceuticals Canada Inc.Financial_Report.xls
10-Q - QUARTERLY REPORT - Tribute Pharmaceuticals Canada Inc.tbuff_10q.htm
EX-10.4 - WARRANT INDENTURE, DATED JULY 15, 2014, BETWEEN TRIBUTE PHARMACEUTICALS CANADA INC. AND EQUITY FINANCIAL TRUST COMPANY. - Tribute Pharmaceuticals Canada Inc.tbuff_ex104.htm
EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED
PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002)

I, Rob Harris, Chief Executive Officer, of Tribute Pharmaceuticals Canada Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 
1.
The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2014 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2014

 
/s/ Rob Harris
 
Rob Harris
 
President and Chief Executive Officer

Tribute Pharmaceuticals Canada Inc. Reports